Loading...
OTCM
RBSH
Market cap3kUSD
Jul 07, Last price  
0.00USD
1Q
0.00%
IPO
-99.89%
Name

Rebus Holdings Inc

Chart & Performance

D1W1MN
OTCM:RBSH chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1,005.17%
Rev. gr., 5y
%
Revenues
0k
Net income
-1m
L
-691,000-3,326,261-5,133,000-4,257,839-5,714,000-6,920,000-5,302,000-6,994,000-5,886,000-3,555,000-11,100,000-12,000-934,000-6,295,0002,698,000-1,020,000
CFO
-706k
L+1.88%
-78,028-2,649,977-2,010,483-2,769,217-3,744,055-4,521,000-4,707,000-5,044,000-4,633,000-2,733,000-1,092,000-204,000-313,000-374,000-693,000-706,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
URL
https://www.rebus-corp.com
IPO date
Nov 02, 2009
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT